These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 7555264)
21. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma. Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245 [TBL] [Abstract][Full Text] [Related]
22. Prostate cancer vaccines: current status. Hwang LC; Fein S; Levitsky H; Nelson WG Semin Oncol; 1999 Apr; 26(2):192-201. PubMed ID: 10597730 [TBL] [Abstract][Full Text] [Related]
23. Minimum safety requirements for preclinical testing. Dorner F; Barrett PN; Schwartz HP; Eibl H Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809 [TBL] [Abstract][Full Text] [Related]
24. Who Expert Committee on Biological Standardization. World Health Organization World Health Organ Tech Rep Ser; 2004; 926():1-109. PubMed ID: 15918537 [TBL] [Abstract][Full Text] [Related]
25. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045 [TBL] [Abstract][Full Text] [Related]
26. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology]. Chiron MF Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366 [TBL] [Abstract][Full Text] [Related]
27. WHO Expert Committee on Biological Standardization. Forty-sixth Report. World Health Organ Tech Rep Ser; 1998; 872():i-vii, 1-90. PubMed ID: 9615608 [TBL] [Abstract][Full Text] [Related]
32. Human vaccine research and development: an overview. Kieny MP; Girard MP Vaccine; 2005 Dec; 23(50):5705-7. PubMed ID: 16182415 [TBL] [Abstract][Full Text] [Related]
33. New developments in the use of cytokines for cancer therapy. Maini A; Morse PD; Wang CY; Jones RF; Haas GP Anticancer Res; 1997; 17(5B):3803-8. PubMed ID: 9427784 [TBL] [Abstract][Full Text] [Related]
34. Immunotoxicology IV - innovative methods and applications for risk assessment in pharmaceutical development: introduction to the conference. House RV J Immunotoxicol; 2008 Jan; 5(1):1. PubMed ID: 18382851 [No Abstract] [Full Text] [Related]
36. Recent progress on the total synthesis of natural products in China. Wu Q; Ma D Nat Prod Rep; 2006 Oct; 23(5):772-88. PubMed ID: 17003909 [TBL] [Abstract][Full Text] [Related]
38. WHO Expert Committee On Biological Standardization. World Health Organ Tech Rep Ser; 1998; 878():i-vi, 1-101. PubMed ID: 9731464 [TBL] [Abstract][Full Text] [Related]
39. WHO Expert Committee on Biological Standardization. World Health Organization World Health Organ Tech Rep Ser; 2006; 932():v-vi, 1-137. PubMed ID: 17274191 [TBL] [Abstract][Full Text] [Related]
40. [Cytokines. Basic research as the basis for therapeutic innovations]. Uhl D Med Monatsschr Pharm; 1988 Apr; 11(4):147-50. PubMed ID: 3288852 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]